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The Hypocalcemic Effects of Actinomycin D
and Mithramycin
Eduardo L. Reyes, M.D.* and Robert W. Talley, M.D.**

Both actinomycin D and mithramycin are useful agents in the treatment of cancer.
They can also produce hypocalcemia, a comparatively rare phenomenon in cancer.
Two such cases are presented in detail. Neither patient had the classic symptoms of
hypocalcemia. Instead, the clinical picture was more compatible with hypercalcemia. The mechanism of action of each drug is explained; therapeutic
implications
are made with regards to their synergistic effects when used in combination
with
the standard calcium-lowering agents. Attention is drawn to the inhibitory action of
these two agents on the calcium-mobilizing
effect of the parathyroid hormone. The
hypocalcemic effects of these two drugs are peripheral and not due to inhibition of
parathyroid hormone synthesis. Because of their potentially fatal biochemical side
effects, extreme caution is advocated in their use.

Hypercalcemia is a common medical emergency in patients with neoplastic disease, either as a result of the
malignancy or as a result of therapy.
Hypocalcemia, however, is a relatively
rare phenomenon in a patient with cancer. Conditions unrelated to cancer can
give rise to hypocalcemia, eg, rickets,
osteomalacia, chronic renal failure,
idiopathic hypoparathyroidism as a
postoperative complication of thyroidectomy, and moniliasis of the parathyroid gland.''^ Neoplasms may also
cause hypocalcemia dhectly or as a result of their associated complications.

For example, medullary carcinoma of
the thyroid may produce hypocalcemia
by secretion of large amounts of thyrocalcitonin, which is a hypocalcemic factor.3 Hypocalcemia may also occm:
spontaneously in lung tumors, and has
been described in carcinoma of the
prostate due to sequestration of calcium
into the areas of osteoblastic metastases.*'^ Breast cancer which has responded dramatically to therapy may
also result in hypocalcemia by relatively rapid deposition of calciiun in lytic
areas in the bone.* Indirectly, other
conditions associated with cancer may
also produce hypocalcemia, eg, hypoalbuminuria due to severe debilitation
and chronic malnutrition, malabsorption syndrome which sometimes accompanies lymphomas, and chronic
renal failure due to secondary metastases to the kidney.

* Now at Howell State Hospital, Howell
Michigan.
'•'* Division of Oncology, Department of
Medicine.
Dr. Reyes was a Fellow-in-Oncology. This
study was supported in part by Public
Health Service Research Grants CA03357 and CA-04915.

Various drugs such as steroids,"
115

Reyes and Talley
phosphates, sulfates, ethylene diaminetetriacetate (EDTA), and thyrocalcitonin — which lower serum calcium
levels — have been used in the management of hypercalcemia.
This paper will present the complications of hypocalcemia induced by
actinomycin D and mithramycin in two
patients. The mechanism of action of
the drugs wiU be discussed in relation
to the homeostasis of calcium metabolism.

crest bone marrow aspiration revealed a M E
ratio of 11.2:1, and decreased normoblasts
but no evidence of tumor cells. The electrocardiogram (EKG) was within normal limits.
X-rays of the chest revealed a superior
mediastinal mass and a postoperative deformity of the fourth right rib. Skeletal xrays demonstrated a lytic lesion of the left
ischium and left tibia.
Since the patient had extensive metastatic
disease with recurrence of lesions previously
radiated, he was considered a candidate for
chemotherapy with vincristine and antinomycin D." The program of therapy was 3.7
mg of vincristine on the first day with 0.7
mg of actinomycin D on the next three days.
Late during the second day of therapy, he
developed chills and fever. However, the following day his temperature returned to normal. A t this time, he developed tachycardia,
tachypnea and anxiety. On the fourth day,
these symptoms increased in severity and the
deep tendon reflexes were absent. A n E K G
revealed only sinus tachycardia. The serum
electrolytes were: sodium 120 mEq/L, potassium 3.6 mEq/L, chlorides 86 mEq/L,
carbon dioxide 17 mEq/L, and serum calcium 6.8 mg/100 cc. The serum enzymes,
which had been normal prior to chemotherapy, were: SGOT of 550 units, L D H
4,750 units and creatine phosphokinase
(CPK) 189 units. The Hgb was 10.4 gm/100
cc; WBC 14,700/cu mm, and platelet count
50,000/cu mm. On the fifth day (one day
after completion of the course of therapy)
he became weak and lethargic, and complained of nausea and dryness of the mouth.
Neurological examination again revealed the
absence of deep tendon reflexes but no evidence of increased muscular irritability or a
positive Chvostek's sign. A t this time, the
serum calcium had fallen to 5.2 mg/100 cc.
A few hours later, the patient lapsed into a
coma. Despite therapy with 10 cc of 10%
calcium gluconate hourly for four doses, he
deteriorated and died. The blood pressure
was normal and stable until one hour prior
to death.

Case Reports
Case I
H.W., a 41-year-old white male had a
thoracotomy in February, 1968, for an undifferentiated carcinoma of the right lung.
Following diagnosis, the patient developed
lytic osseous metastases to the left tibia and
left ischium. These responded well to cobalt
therapy. He had a persistent leucocytosis,
with no clinical infection. In December,
1968, the patient complained of dull discomfort in the right rib cage, progressive weakness, anorexia, and weight loss. Persistence
of this pain necessitated admission to the
hospital on January 10, 1969.
At time of admission, pertinent physical
findings revealed a thin middle-aged man
complaining of weakness and pain in the
right lateral rib cage. Blood pressure was
120-80, pulse 80/minute and regular, and
temperature was 100.2°F. Except for tenderness i n the well-healed right thoracotomy
scar, a 3 X 3 cm firm tender mass over the
left ischium, and prominence of the middle
portion of the tibia, the physical examination was not unusual.
Pertinent laboratory findings were: hemoglobin (Hgb) 10 gm/100 cc; white blood count
(WBC) 17,000/cu mm; platelet count 524,300/cu mm; polymorphonuclear leucocytes
82%, lymphocytes 11%, bands 1%; urinalysis normal; fasting blood sugar (FBS) 105
mg/100 cc; urea nitrogen 12 mg/100 cc;
alkaline phosphatase 6.8 Bodansky units;
total bilirubin 0.64 mg/100 cc; direct bilirubin 0.32 mg/100 cc; serum calcium 11.3
mg/100 cc, phosphate 3.6 mg/100 cc, serum
glutamic oxaloacetic transaminas3 (SGOT)
15 units, lactic dehydrogenase (LDH) 260
units; albumin 3.07 gm/100 cc; and
globulin 0.43%,a„ globulin 1.31 gm%, /3 globulin
1.09 gm%, and 7 globulin 1.97 gm%. Iliac

At autopsy no evidence of acute myocardial infarction or pulmonary embolism
was found. There was a tumor in the right
upper lobe infiltrating the pleura, superior
mediastinum, esophageal serosa, adventitia
of the aorta, and periosteum of the adjacent
thoracic vertebra. There was also tumor involvement of the left ischium and left tibia.
The parathyroid glands were within normal
limits.
Case II
G.O., a 27-year-old white male, was re-
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ferred to Henry Ford Hospital on June 19,
1966, for chemotherapy of metastatic embryonal carcinoma of the testis. He had undergone an orchiectomy in October, 1964, at
another institution, followed by radio therapy
to pelvic and para-aortic nodes. An abdominal mass and ascites developed in February, 1966, but treatment with cyclophosphamide and vinblastine resulted in a brief
regression. Pertinent physicalfindingsat time
of admission were: a mass measuring 7 x 8
cm in the left supraclavicular area, dullness
to percussion of the bilateral chest, hepatomegally 8 cm below the right costal margin, and a firm, hard 15 x 13 cm mass in the
left upper abdomen.
Pertinent initial laboratory findings were
as follows: Hgb 14.3 gm/100 cc; WBC 18,000/cu mm; platelet count 350,000/cu mm;
neutrophils 84%; lymphocytes 9%; monocytes 1%; bands 6%. Urinalysis showed specific gravity to be 1.026, albumin -)-2, occasional epithelial cells, RBC 10-12. Serum
alkaline phosphatase was 7.4 Bodansky
units; serum bilirubin 1.6; serum calcium 10
mg/100 cc; and urea nitrogen 45 mg/100
cc. X-ray films of the chest revealed bilateral pleural effusion and enlarged mediastinal nodes. Upper gastrointestinal study revealed a complete obstruction of the fourth
portion of the duodenum by a large retroperitoneal mass, and an intravenous pyelogram revealed minimal hydronephrosis bilaterally.
On June 21, 1968, the patient was started
on a course of mithramycin 1.75 mg/day
given in an 8-hour intravenous infusion. His
serum calcium fell to 8.6 mg/100 cc the
following day from an initial level of 10 mg/
100 cc prior to therapy. This continued to
fall steadily so mithramycin was discontinued after nine days. Even though his serum
calcium level fell to 6.2 mg/100 cc, the
patient manifested no increased muscular irritability or other signs and symptoms of
classic hypocalcemia. The serum urea nitro-

gen rose progressively to 72 mg/100 cc. A
slight decrease was noted in the size of the
cervical and abdominal mass following
mithramycin therapy. The serum calcium
gradually returned to normal (Fig 1) even
though the serum urea nitrogen increased
slowly to 90 mg/100 cc 14 days after completion of therapy. By that time the serum
calcium had returned to a normal level of
10.2 mg/100 cc. Because of the persistent intestinal obstruction the patient's condition
deteriorated and he died.
The autopsy revealed bilateral bronchopneumonia and metastases to the para-aortic
and mediastinal nodes, both adrenals, liver,
left kidney, vertebra, and left cervical nodes.
The parathyroids were normal.
Discussion
Even though the exact etiology of the
hypocalcemia in these two patients was
not conclusively proven, the most likely
explanation was the effect on calcium
homeostasis by the two chemotherapeutic agents employed. The time relationship between drug administration
and the onset of hypocalcemia favors
this; also the fact that these patients
had high calcium levels (Case f l —
H.W.) and a normal serum calcium
prior to therapy (Case #11 — CO.). In
both cases, the patients had none of the
signs frequently associated with hypocalcemia such as increased muscular
irritability and hyperactive reflexes. On
the contrary, the signs and symptoms
could be confused with hypercalcemia.
However, part of the symptomatology
of Case #1 could be explained on the
basis of metabolic acidosis and low
sodium, chlorides, and potassium which
may account for the hyperventilation as
well as lethargy and areflexia. Vincristine may also have contributed to the
areflexia. However, there are no reported instances of hypocalcemia occurring with vincristine therapy. The
markedly elevated serum enzymes may
have resulted from necrosis of normal
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Changes in serum calcium and phosphate in
Case #2 (G. O.) with mithramycin therapy.
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and/or tumor tissue caused by these
agents.
Actinomycin D, an antibiotic, was
first discovered by Waksman and
Woodruff in 1940 and found to be an
effective antibacterial agent, but it is
too toxic to be used clinically as an
antibacterial agent,
Antinomycin
produces selective toxicity to the bone
marrow, lymphoid tissue, and intestinal
epithelium, and in this respect is similar
to other cancer chemotherapeutic
agents.8 In humans, antinomycin D has
also been found to be effective in treatment of neuroblastomas, Wilm's tumor,
choriocarcinoma, and testicular neoplasms.i» The combination of antinomycin D and vincristine has been reported to be effective in the therapy
of lung cancer.'^
This agent has also been found to
produce profound biochemical effects
including the antagonism of the action
of parathyroid hormones." Antinomycin binds to guanine of the deoxyribonucleic acid (DNA) chain, thus mhibiting the synthesis of messenger ribonucleic acid (MRNA). With MRNA
synthesis inhibited, further RNA synthesis is blocked.13 Although the exact
mechanism of interference with parathyroid hormonal action is unclear, it is
believed to depend upon induction of
an enzyme system which blocks parathormone or Vitamin D action.^'i^
Parathormone induces the synthesis of
MRNA which regulates enzyme production. Actinomycin D probably does
not interfere with the synthesis of hormones but blocks peripheral action. In
animal experiments, actinomycin prevents serum calcium elevations m Vitamin D-deficient rats given either Vitamin D or parathyroid hormone, i^-ie
It is generally accepted that the para-

thyroid hormone influences the kidneys,
gastrointestinal tract, and (more profoundly) bone. Vitamin D has a similiar
action, increasing the permeability of
the intestinal mucosa to calcium^^ and
also causing
morphologic
bone
changes. 1* Actinomycin D is antagonistic to these two effects of Vitamin D
because it inhibits the calcium transport
system in the gastrointestinal tracfi*
and suppresses hypercalcemia and
morphologic bone changes induced by
the vitamin." i5.i7
Previous experiments also have
shown the inhibitory action of antinomycin D on the calcium-mobUizing effect of the parathyroid hormone.i^'i^'i^
It seems that actinomycin D blocks this
effect on the bone but is not effective
against the phosphoturic action of the
parathyroid hormone. To further confirm the hypocalcemic effect of actinomycin D, it has been shown that recovery from hypocalcemia is delayed
in rats treated with actinomycin D after
administration of thyrocalcitonin.^" The
hypocalcemic effect of actinomycin D
is usually delayed from 7 to 12 hours
after administration. A hypothesis offered for this speculates that, with the
inhibition of a parathyroid hormone,
thyrocalcitonin and steroids would be
free to exert their effects unopposed,
Mithramycin, another antibiotic, also
produces hypocalcemia. Historically,
this drug was derived from an Actinomycete culture belonging to the genus
Streptomyces. It was first shown to be
active against HeLa ceUs in tissue culture, adenocarcinoma 755 as well as
gram positive bacteria in 1960.^0 In the
same year, Curreri and Ansfield published the first clinical evaluation of the
drug in solid tumors, reporting regressions in two patients. Toxic effects

118

The Hypocalcemic Effects of Actinomycin D and Mithramycin
noted were nausea, vomiting, acute
renal failure, and hematopoietic toxicity
of severe thrombocytopenia.-^ There
was no mention of hypocalcemia.

also diminished thereby ruling out the
possibility of rapid bone repair.-* He
also suggested that mithramycin might
block the osteolytic sterols.

Parker et al gave the drug to 19
patients in 1960 and formed the same
conclusions.— In 1963, Koffman reported the results of therapy usmg the
drug in 84 patients, with regressions
observed in six patients. Besides the
usual side effects noted by previous investigators, he reported hypocalcemia
in two patients.-^ In 1965, Brown and
Kennedy also noted significant reduction in serum calcium and phosphorus,
with one patient developing symptomatic hypocalcemia.-* In 1966, Koons
also encountered hypocalcemia in his
patients.-'' In 1968, Ream reported regressions in 9 of 26 evaluable patients.
Three of his patients developed hypocalcemia, two of them symptomatic and
the other one asymptomatic^^ Talley
also noted hypocalcemia (less than 8
mg%) in 10 of 51 patients given this
drug for aU types of solid tumors.-^
Also, none of these patients had symptoms suggestive of hypocalcemia but
many had symptoms that were more
suggestive of hypercalcemia.

Summary
Two patients are reported with hypocalcemia, one secondary to actinomycin D and one incidental to mithramycin. Neither patient had the classic
symptoms of increased muscular irritability associated with hypocalcemia.
Instead, the clinical picture was more
compatible with hypercalcemia. The
mechanism of action of these two drugs
is identical. Both inhibit MRNA production which is necessary for enzyme
synthesis. Such enzyme synthesis is
vital for hormonal action. The hypocalcemic effects of these two drugs are
peripheral and not due to inhibition of
parathyroid hormone synthesis. Review
of the literature shows that these drugs
have an antagonistic action on the hypercalcemic effects of parathyroid hormone and Vitamin D in laboratory animals. Because of this easily unrecognized complication, attention should be
directed toward biochemical side effects as well as known bone marrow
toxic effects. Therapeutically, actinomycin D or mithramycin might be used
cautiously in the treatment of hypercalcemia when other accepted modalities of therapy have failed.

Mithramycin has also been shown to
inhibit RNA synthesis. Most probably
this is also accomplished by binding to
DNA like antinomycin D.-'^ With this
inhibition, the enzyme system necessary for hormone action is also
blocked. The hypocalcemic action of
mithramycin has been reported in a
controlled study by Parsons.-* Patients
with cancer, given mithramycin,
showed a reduction in urinary calciimi
reflecting a decrease in serum calcium.
Urinary hydroxyproline excretion was
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